Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

(2023) Hiddo J L Heerspink et al.   LANCET

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

(2023) Dana V. Rizk et al.   Kidney International Reports

Urinary C5b-9 as a Prognostic Marker in IgA Nephropathy

(2022) Byung Chul Yu et al.   Journal of Clinical Medicine

Oral Glucocorticoids for IgA Nephropathy

(2022) Kirk N. Campbell   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy

(2022) Jicheng Lv et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

(2022) Jonathan Barratt et al.   KIDNEY INTERNATIONAL

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

(2022) Regis Peffault de Latour et al.   BLOOD

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

(2022) Colin Baigent et al.   LANCET

Empagliflozin in Patients with Chronic Kidney Disease

(2022)   NEW ENGLAND JOURNAL OF MEDICINE

Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis

(2021) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

SGLT-2 inhibition in IgA nephropathy: the new standard of care?

(2021) Jonathan Barratt et al.   KIDNEY INTERNATIONAL

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

(2021) David C. Wheeler et al.   KIDNEY INTERNATIONAL

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

(2021) Antonio M Risitano et al.   Lancet Haematology

Is IgA nephropathy the same disease in different parts of the world?

(2021) Hong Zhang et al.   Seminars in Immunopathology

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy

(2021) Chee Kay Cheung et al.   Journal of Clinical Medicine

Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy

(2021) Feng Ping Ji et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

(2021) Brad H. Rovin et al.   KIDNEY INTERNATIONAL

Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals

(2021) Lukas Muri et al.   Frontiers in Immunology

Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals

(2021) Emma Ispasanie et al.   Frontiers in Immunology

The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

(2021) Felix Poppelaars et al.   Journal of Clinical Medicine

C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study

(2021) Annette Bruchfeld et al.   Clinical Kidney Journal

Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort

(2021) Suceena Alexander et al.   Kidney International Reports

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

(2020) Thomas Rauen et al.   KIDNEY INTERNATIONAL

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy

(2020) Richard Lafayette et al.   Kidney International Reports

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

(2019) Aliza Thompson et al.   Clinical Journal of the American Society of Nephrology

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

(2019) Anna Schubart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy

(2019) Sean J. Barbour et al.   JAMA Internal Medicine

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

(2019) Lesley A. Inker et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

(2019) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications

(2018) Dani A.C. Heesterbeek et al.   Journal of Innate Immunity

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy

(2017) Jicheng Lv et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Circulating complement factor H–related proteins 1 and 5 correlate with disease activity in IgA nephropathy

(2017) Nicholas R. Medjeral-Thomas et al.   KIDNEY INTERNATIONAL

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

(2017) Hernán Trimarchi et al.   KIDNEY INTERNATIONAL

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

(2017) Bengt C Fellström et al.   LANCET

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis

(2016) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

IgA nephropathy

(2016) Kar Neng Lai et al.   Nature Reviews Disease Primers

Current Understanding of the Role of Complement in IgA Nephropathy

(2015) N. Maillard et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

(2015) Thomas Rauen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complement System Part I – Molecular Mechanisms of Activation and Regulation

(2015) Nicolas S. Merle et al.   Frontiers in Immunology

Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease

(2013) Sean J. Barbour et al.   KIDNEY INTERNATIONAL

Model-based dose finding under model uncertainty using general parametric models

(2013) José Pinheiro et al.   STATISTICS IN MEDICINE

Genome-wide association study identifies susceptibility loci for IgA nephropathy

(2011) Ali G Gharavi et al.   NATURE GENETICS

Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function

(2011) Kisara Onda et al.   BMC Nephrology

The incidence of primary glomerulonephritis worldwide: a systematic review of the literature

(2010) A. McGrogan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION